Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
Sixteen patients with adult metastatic renal cell carcinoma were treated with elliptinium acetate, 80 mg/m2.day, for 3 consecutive days every 3 weeks. Among the 14 patients evaluable, no objective effects were observed. The toxicity was mild and no patients experienced intravascular hemolysis.
Piot
G
G
Service de Médecine, Institut Gustave-Roussy, Villejuif, France.
Droz
J P
JP
Theodore
C
C
Ghosn
M
M
Rouëssé
J
J
Amiel
J L
JL
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D004611:Ellipticines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; C027767:elliptinium